The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...